Pyxis Oncology FY2024 EPS Forecast Lowered by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Stock analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of Pyxis Oncology in a report issued on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($1.00) per share for the year, down from their prior forecast of ($0.89). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.46) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.44) EPS and FY2028 earnings at ($0.75) EPS.

PYXS has been the subject of several other reports. Royal Bank of Canada reissued an “outperform” rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Thursday, September 19th. Stephens began coverage on Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price objective for the company. Finally, Stifel Nicolaus started coverage on Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 target price on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $9.57.

Pyxis Oncology Trading Down 2.1 %

PYXS opened at $4.19 on Friday. The company has a fifty day moving average price of $3.69 and a two-hundred day moving average price of $3.65. Pyxis Oncology has a 1-year low of $1.35 and a 1-year high of $6.85. The company has a market cap of $249.16 million, a P/E ratio of -4.07 and a beta of 1.27.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04.

Institutional Investors Weigh In On Pyxis Oncology

A number of large investors have recently added to or reduced their stakes in PYXS. Fullcircle Wealth LLC purchased a new position in Pyxis Oncology during the second quarter valued at $40,000. Intech Investment Management LLC purchased a new stake in shares of Pyxis Oncology during the 3rd quarter valued at about $55,000. SG Americas Securities LLC bought a new stake in shares of Pyxis Oncology in the third quarter worth approximately $58,000. The Manufacturers Life Insurance Company purchased a new position in shares of Pyxis Oncology during the second quarter valued at approximately $65,000. Finally, MetLife Investment Management LLC lifted its position in Pyxis Oncology by 41.1% during the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after purchasing an additional 5,484 shares during the period. Institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.